CA2815239C - Fviii peptides for immune tolerance induction and immunodiagnostics - Google Patents

Fviii peptides for immune tolerance induction and immunodiagnostics Download PDF

Info

Publication number
CA2815239C
CA2815239C CA2815239A CA2815239A CA2815239C CA 2815239 C CA2815239 C CA 2815239C CA 2815239 A CA2815239 A CA 2815239A CA 2815239 A CA2815239 A CA 2815239A CA 2815239 C CA2815239 C CA 2815239C
Authority
CA
Canada
Prior art keywords
peptide
amino acids
amino acid
fviii
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2815239A
Other languages
English (en)
French (fr)
Other versions
CA2815239A1 (en
Inventor
Katharina Nora Steinitz
Paula Maria Wilhelmina Van Helden
Birgit Maria Reipert
Hans-Peter Schwarz
Hartmut Ehrlich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Baxalta GmbH
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Inc filed Critical Baxalta GmbH
Publication of CA2815239A1 publication Critical patent/CA2815239A1/en
Application granted granted Critical
Publication of CA2815239C publication Critical patent/CA2815239C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56977HLA or MHC typing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
CA2815239A 2010-10-27 2011-10-27 Fviii peptides for immune tolerance induction and immunodiagnostics Active CA2815239C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US40740210P 2010-10-27 2010-10-27
US61/407,402 2010-10-27
US201161467894P 2011-03-25 2011-03-25
US61/467,894 2011-03-25
US201161502476P 2011-06-29 2011-06-29
US61/502,476 2011-06-29
PCT/US2011/058165 WO2012058480A1 (en) 2010-10-27 2011-10-27 Fviii peptides for immune tolerance induction and immunodiagnostics

Publications (2)

Publication Number Publication Date
CA2815239A1 CA2815239A1 (en) 2012-05-03
CA2815239C true CA2815239C (en) 2019-02-26

Family

ID=45349271

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2815239A Active CA2815239C (en) 2010-10-27 2011-10-27 Fviii peptides for immune tolerance induction and immunodiagnostics

Country Status (20)

Country Link
US (3) US8969524B2 (https=)
EP (2) EP3260132B1 (https=)
JP (2) JP6122780B2 (https=)
KR (2) KR102040867B1 (https=)
CN (2) CN103298482B (https=)
AR (1) AR083586A1 (https=)
AU (2) AU2011319747C1 (https=)
BR (1) BR112013010362A2 (https=)
CA (1) CA2815239C (https=)
DK (1) DK2632479T3 (https=)
EA (1) EA034494B1 (https=)
ES (2) ES2912455T3 (https=)
HK (1) HK1215442A1 (https=)
MX (1) MX347805B (https=)
NZ (2) NZ703514A (https=)
PL (2) PL2632479T3 (https=)
PT (1) PT2632479T (https=)
SG (2) SG189914A1 (https=)
TW (3) TWI580430B (https=)
WO (1) WO2012058480A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063031A2 (en) 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
RS56069B1 (sr) * 2012-11-12 2017-10-31 Apitope Int Nv Faktor viii-izvedenih peptida za upotrebu u lečenju hemofilije a
EP2928303A4 (en) 2012-12-07 2016-07-13 Haplomics Inc FACTOR VIII MUTATION REPAIR AND TOLERANCE INDUCTION
US20160038575A1 (en) * 2013-03-15 2016-02-11 Haplomics, Inc. Compositions and methods for immune tolerance induction to factor viii replacement therapies in subjects with hemophilia a
CA2951150C (en) * 2014-06-12 2024-05-28 University Of Hawaii Uses of humanized cobra venom factor for reducing or preventing immunogenicity
ES2869972T3 (es) * 2015-01-26 2021-10-26 Cellectis Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas
KR102415992B1 (ko) 2016-04-15 2022-07-04 다케다 야쿠힌 고교 가부시키가이샤 약물동역학 약물 투약 요법을 제공하는 방법 및 장치
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538694A (ja) * 2002-04-18 2005-12-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 修飾されたviii因子
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
ATE427499T1 (de) * 2004-05-21 2009-04-15 Inst Systems Biology Zusammensetzungen und verfahren zur quantifizierung von serumglykoproteinen
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
EP3653699A1 (en) 2006-01-04 2020-05-20 Baxalta Incorporated Oligopeptide-free cell culture media
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
US7673687B2 (en) 2007-12-05 2010-03-09 Halliburton Energy Services, Inc. Cement compositions comprising crystalline organic materials and methods of using same
DE202007017320U1 (de) 2007-12-07 2008-02-28 Dittmann, Ludwig Vorrichtung zur Raumbeduftung
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII
US20110081362A1 (en) 2008-01-31 2011-04-07 The Brigham And Women's Hospital, Inc. Treatment of cancer
NZ593190A (en) 2008-11-07 2013-01-25 Baxter Int Factor viii formulations

Also Published As

Publication number Publication date
CA2815239A1 (en) 2012-05-03
EP3260132A1 (en) 2017-12-27
KR20130128404A (ko) 2013-11-26
TW201708251A (zh) 2017-03-01
AU2011319747C1 (en) 2016-07-14
NZ703514A (en) 2017-02-24
HK1215442A1 (zh) 2016-08-26
SG189914A1 (en) 2013-06-28
KR102222864B1 (ko) 2021-03-04
EP2632479A1 (en) 2013-09-04
JP2014505014A (ja) 2014-02-27
AU2016202155A1 (en) 2016-04-28
TW201231065A (en) 2012-08-01
MX2013004753A (es) 2013-09-13
SG10201600656WA (en) 2016-02-26
US20120135019A1 (en) 2012-05-31
TWI580430B (zh) 2017-05-01
DK2632479T3 (en) 2017-08-07
NZ609474A (en) 2015-06-26
JP6122780B2 (ja) 2017-04-26
MX347805B (es) 2017-05-15
WO2012058480A1 (en) 2012-05-03
US20150203567A1 (en) 2015-07-23
PL2632479T3 (pl) 2017-09-29
PT2632479T (pt) 2017-07-24
US20170267743A1 (en) 2017-09-21
KR20190126189A (ko) 2019-11-08
EA201390617A1 (ru) 2013-10-30
US8969524B2 (en) 2015-03-03
ES2639039T3 (es) 2017-10-25
JP2017095463A (ja) 2017-06-01
EP3260132B1 (en) 2022-02-09
CN103298482B (zh) 2015-08-19
EP2632479B1 (en) 2017-06-14
EA034494B1 (ru) 2020-02-13
KR102040867B1 (ko) 2019-11-07
US9512198B2 (en) 2016-12-06
BR112013010362A2 (pt) 2016-08-02
CN103298482A (zh) 2013-09-11
AU2011319747A1 (en) 2013-05-02
TW201730205A (zh) 2017-09-01
AU2011319747B2 (en) 2016-01-07
PL3260132T3 (pl) 2022-08-08
AU2016202155B2 (en) 2018-02-01
AR083586A1 (es) 2013-03-06
ES2912455T3 (es) 2022-05-26
CN104926947A (zh) 2015-09-23

Similar Documents

Publication Publication Date Title
CA2815239C (en) Fviii peptides for immune tolerance induction and immunodiagnostics
US20040072259A1 (en) Methods and products for manipulating hematopoietic stem cells
HK1246211A1 (en) Fviii peptides for immune tolerance induction and immunodiagnostics
HK1246211B (en) Fviii peptides for immune tolerance induction and immunodiagnostics
HK1188954A (en) Fviii peptides for immune tolerance induction and immunodiagnostics
HK1188954B (en) Fviii peptides for immune tolerance induction and immunodiagnostics
WO2022114798A1 (ko) 자연살해세포 nkg2d 수용체에 결합하는 sars-cov-2 s 단백질 유래 펩타이드를 이용한 자연살해세포 활성 증가 및 감염병, 암 예방 및 치료용 조성물
US8658177B2 (en) Promiscuous HER-2/Neu CD4 T cell epitopes
EA043749B1 (ru) Пептиды фактора viii для индукции иммунной толерантности и иммунодиагностики
US20120201792A1 (en) Methods and products for manipulating hematopoietic stem cells
ES2282148T3 (es) Metodos y moleculas inmunoterapeuticos.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161025

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240930

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240930

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251216